New ESH guidelines: focus on comorbidities and new treatments
Prof. Konstantinos Tsioufis
Director, 1st Dept of Cardiology, Hippokration Hospital of Athens, Professor of Cardiology, National and Kapodistrian Univ. of Athens
Disease: Cardiovascular diseases (CVD) , Diabetes , Hypertension
Specialties: Cardiology
Tags: Beta blockers (drugs) , Renal Denervation , Sacubitril/Valsartan (LCZ696), treatment with , SGLT-2-inhibitors (gliflozins)
Director, 1st Dept of Cardiology, Hippokration Hospital of Athens, Professor of Cardiology, National and Kapodistrian Univ. of Athens
Disease: Cardiovascular diseases (CVD) , Diabetes , Hypertension
Specialties: Cardiology
Tags: Beta blockers (drugs) , Renal Denervation , Sacubitril/Valsartan (LCZ696), treatment with , SGLT-2-inhibitors (gliflozins)
Hypertension, an underestimated threat. The new tools to fight it
it
Prof. Stefano Taddei
ESH Guidelines 2023: improving the control of hypertension as a risk factor
it
Prof. Gianfranco Parati
A study on patient preferences for renal denervation or drugs
en
Prof. Atul Pathak
New ESH guidelines: focus on comorbidities and new treatments
en
Prof. Konstantinos Tsioufis
Uncontrolled hypertension: a paradigmatic clinical case
en
Prof. Roland Schmieder
Two clinical cases on renal denervation treatment
en
Prof. Yaron Arbel
Antihypertensive drugs: novelties and re-evaluations in the ESH guidelines
en
Prof. Michel Burnier
Functional status, not the age, is the criterion for elderly treatment
en
Prof. Athanasios Benetos
Preventing stroke and dementhia. The new targets
en
Prof. Dagmara Hering
Blood pressure control after a stroke
en
Prof. Alastair Webb